# Study to Evaluate the Safety and Tolerability of EP0042

Source: https://onco.cc/trials/nct04581512/  
OnCo record `nct04581512` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Venetoclax and Azacitidine in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Ellipses Pharma, now recruiting.

## Summary

Study to Evaluate the Safety and Tolerability of EP0042 is a phase 1/2 interventional study registered as NCT04581512 by Ellipses Pharma, with 70 participants planned, started 2020-11-02 and due to reach its primary completion in 2027-12. Interventions recorded: EP0042, Venetoclax and Azacitidine (AZA).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04581512
- Phase: 1/2
- Setting: A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
- Sponsor: Ellipses Pharma
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT04581512: https://clinicaltrials.gov/study/NCT04581512

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04581512.json